Pomalidomide/Strong CYP1A2 or CYP3A4 Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your body processes pomalidomide.
What might happen:
The amount of pomalidomide in your blood may increase and cause more or more severe side effects than expected.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to adjust the dose of your pomalidomide or do more blood tests while you are taking the other medicine. Let your doctor know right away if you develop any unusual bleeding, bruising, fatigue, sore throat, shortness of breath, chills, aches, fever, nausea, vomiting, dizziness, weakness or rash.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 2013 Feb;71(2):489-501.
2.Pomalyst (pomalidomide) US prescribing information. Celgene Corporation February, 2013.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
